Given that PTEN integrity is protective against MMR deficiency in several types of tumor [18,19,20], and that IHC is an excellent technique for identifying tumors with functional inactivation of this tumor suppressor [16,25,26], we have hypothesized that PTEN IHC can be of clinical value in MMR status assessment in breast cancers. This evidence concerns the gene MRC1 and breast carcinoma.